Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands

BACKGROUND: Use of the direct oral anticoagulant rivaroxaban has strongly increased in Europe since its market approval for non-valvular atrial fibrillation in 2011. Patients characteristics of rivaroxaban initiators may have changed over time but this has not been investigated so far. OBJECTIVE: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Voss, Annemarie, Smits, Elisabeth, Swart, Karin M. A., Balabanova, Yanina, Brobert, Gunnar, Suzart-Woischnik, Kiliana, Herings, Ron M. C., Schink, Tania, Haug, Ulrike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232386/
https://www.ncbi.nlm.nih.gov/pubmed/36725812
http://dx.doi.org/10.1007/s40801-022-00350-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232386/
https://www.ncbi.nlm.nih.gov/pubmed/36725812
http://dx.doi.org/10.1007/s40801-022-00350-2

Ejemplares similares